BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.82 USD
+0.01 (1.26%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.82 0.00 (-0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 61 - 80 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
We are transferring coverage due to the departure of the covering analyst. Shares will remain rated Under Review
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Stage Now Set to Go Pivotal; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Stage Now Set to Go Pivotal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Pipeline Expanding as Expected; Coffers Filled to the Brim; Target Raised to $4
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Pipeline Expanding as Expected; Coffers Filled to the Brim; Target Raised to $4
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
While ''8040 Continues its March Forward, It''s the Year of Background BD and Focus; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
While ''8040 Continues its March Forward, It''s the Year of Background BD and Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Initiating Coverage at Buy Rating
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Looking for BL-8040 to Rule the Roost; Enticing Shots on Goal; Initiating Coverage at Buy
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
We are transferring coverage of BLRX to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
''8040 One Two Punch Highlighted at ASH; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q16 Results; Cash Strong and Upcoming Data Rich; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Rolling Out Another License with Novartis Collaboration
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J